Is the UK Medical Cannabis System Stuck Between Legality and Funding?

Since 2018, medical cannabis has been legal to prescribe in the UK under very controlled circumstances. But “legal” does not automatically mean easy to access on the NHS. In fact, patients and clinicians often find themselves caught in a confusing bind where cannabis medicines are lawful but rarely funded, creating what feels like a two-tier healthcare system.

Let’s unpack what actually changed in 2018, why NHS funding rarely follows the legality of prescribing cannabis-based products, and what that means for patients navigating illicit market vs medical cannabis both the system and out-of-pocket private options. We’ll also highlight helpful tools such as medicalcannabis.co.uk — a clinic directory and comparison site — and releaf.co.uk, which has solid explainer links on the topic.

The 2018 Rescheduling: What Changed?

Before November 2018, cannabis was listed under Schedule 1 of the Misuse of Drugs Regulations 2001 — meaning it was considered to have no medicinal value and was illegal to prescribe. This blanket ban meant even specialist doctors could not legally prescribe cannabis-based products for medicinal use, forcing many patients to seek unregulated black-market supplies.

However, following a landmark review, cannabis-based medicinal products (CBMPs) were moved to Schedule 2, which includes drugs such as morphine and methadone. This shift recognised cannabis medicines as having legitimate medical use under strict controls.

• Schedule 2 cannabis UK
  • Specialist doctors on the General Medical Council's Specialist Register may legally prescribe cannabis-based medicinal products.
  • Prescriptions must comply with all regulatory standards, including secure storage and detailed record keeping.
  • GMP (Good Manufacturing Practice) standards apply to these products.

In theory, this change opened the door for medical cannabis prescribing in the NHS. But the reality has proven more complicated.

NHS Funding vs Legality: The Catch-22

Despite the medicines being legal to prescribe by specialists, NHS funding for cannabis-based medicines remains extremely limited. The National Institute for Health and Care Excellence (NICE) has not issued broad guidance recommending routine NHS use of cannabis products for most conditions. This leaves clinical commissioning groups (CCGs) to make local decisions on funding, often declining or setting stringent criteria.

Here’s the straightforward translation for patients: just because a doctor can write a legal prescription for medical cannabis does not mean the NHS will pay for it. That means the vast majority of patients who want these medicines must seek private clinics and pay out of pocket, sometimes to the tune of hundreds or even thousands of pounds monthly.

Unfortunately, no specific prices were stated in the data we have on hand. If pricing figures appear in future sources, quoting them fully and accurately is essential, individual funding request nhs to avoid confusion over cost and affordability.

The Two-Tier Healthcare Dynamic

This disconnect creates a classic two-tier healthcare UK problem:

1. NHS patients may wait months or years, and often get turned down.
2. Private patients pay directly for access to specialist consultations and cannabis medicines from private clinics.

Sites like medicalcannabis.co.uk help patients explore private clinic options and compare costs and services. However, this route is not feasible for everyone, raising serious equity concerns.

Specialist-Only Prescribing Rules and Unlicensed Medicines

The legality also comes with tight restrictions:

• Only specialist consultants on the GMC Specialist Register can prescribe CBMPs. GPs cannot initiate or prescribe these products themselves.
• Many cannabis medicines prescribed are unlicensed, meaning they have not passed through the full MHRA licensing process.

Because unlicensed does not mean illegal, doctors sometimes prescribe unlicensed cannabis products under the “specials” regulations, but NHS policies often express caution around funding these due to lack of robust evidence and cost-effectiveness concerns.

So even if a prescribing specialist is willing, NHS funding bodies may define these products as “experimental” or “not cost-effective,” limiting their availability on the NHS and frustrating both clinicians and patients.

Summary: What Patients Need to Know

Aspect Reality in UK Medical Cannabis System Legality Legal to prescribe Schedule 2 cannabis-based medicines by specialists since 2018. NHS Funding Rare and patchy; often restricted to exceptional cases, leaving many to pay privately. Who Can Prescribe Specialist consultants only; GPs cannot initiate or continue prescriptions. Medicine Licensing Most cannabis medicines are unlicensed “specials,” adding to NHS caution. Patient Access Two-tier: NHS patients face barriers, private patients pay significant fees, aided by clinic directories like medicalcannabis.co.uk.

Useful Resources and Further Reading

• Medical Cannabis UK Clinic Directory & Comparison
• Releaf.co.uk Cannabis Medicines Explainer
• NICE guidance on cannabis-based medicinal products
• Department of Health Cannabis Prescribing FAQs

Conclusion

The UK’s medical cannabis system is indeed stuck in a limbo between legality and funding. The 2018 rescheduling was a landmark legal milestone, but without consistent NHS funding or prescribing flexibility, patients frequently find themselves forced into the private sector, paying substantial sums to access medicines their doctors say could help.

For medical cannabis to move beyond this two-tier healthcare UK issue, policymakers, clinicians, and funding bodies will need to develop clearer, more equitable frameworks that align legality with real-world patient access. Until then, patients and specialists remain caught between “can prescribe” and “can afford.”